| P50 | author | Amelie Stritzke | Q88556938 |
| P2093 | author name string | S Kaur | |
| | A Lodha | |
| | N Kabra | |
| | H L Robertson | |
| P2860 | cites work | Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity | Q24609568 |
| | The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | Q27860647 |
| | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860749 |
| | Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity | Q30883262 |
| | Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial | Q31031681 |
| | The International Classification of Retinopathy of Prematurity revisited | Q34433109 |
| | A randomized, controlled trial of oral propranolol in infantile hemangioma. | Q34668015 |
| | The levels of evidence and their role in evidence-based medicine | Q35072317 |
| | Oral propranolol in early stages of retinopathy of prematurity | Q35914596 |
| | Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy | Q36035023 |
| | The Efficacy of Propranolol in Retinopathy of Prematurity and its Correlation with the Platelet Mass Index | Q36040633 |
| | Prophylactic propranolol for prevention of ROP and visual outcome at 1 year (PreROP trial). | Q36249663 |
| | International variations and trends in the treatment for retinopathy of prematurity. | Q36300200 |
| | The β-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases | Q38220562 |
| | On the use of antiangiogenetic medications for retinopathy of prematurity | Q38906895 |
| | Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity | Q47629197 |
| | Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives | Q47968906 |
| | Retinal vasculature development in health and disease. | Q50054522 |
| | Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. | Q50442563 |
| | Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial. | Q51425178 |
| | Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants. | Q52677056 |
| | Oral propranolol versus placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective study | Q56989404 |
| | Retinopathy of prematurity | Q60439193 |
| | Ophthalmic Insert versus Eye Drops for Mydriasis in Neonates: A Randomized Clinical Trial | Q64120722 |
| | Pathogenesis of retinopathy of prematurity | Q80068666 |
| | Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice | Q86489017 |
| | RoB 2: a revised tool for assessing risk of bias in randomised trials | Q92964533 |
| P2507 | corrigendum / erratum | Correction to: Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and meta-analysis | Q90999776 |
| P433 | issue | 12 | |
| P921 | main subject | retinopathy of prematurity | Q1423087 |
| | systematic review | Q1504425 |
| P304 | page(s) | 1584-1594 | |
| P577 | publication date | 2019-09-30 | |
| P1433 | published in | Journal of Perinatology | Q18626659 |
| P1476 | title | Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and meta-analysis | |
| P478 | volume | 39 | |